MannKind (MNKD) Scheduled to Post Earnings on Wednesday

MannKind (NASDAQ:MNKD - Get Free Report) will issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

MannKind (NASDAQ:MNKD - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. The company had revenue of $58.47 million for the quarter, compared to the consensus estimate of $52.36 million. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Stock Up 0.9 %

MNKD stock traded up $0.04 during trading on Thursday, hitting $4.38. The company had a trading volume of 1,710,103 shares, compared to its average volume of 2,902,629. The firm has a 50-day moving average price of $4.38 and a 200-day moving average price of $3.92. MannKind has a 12 month low of $3.17 and a 12 month high of $5.75. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -86.40 and a beta of 1.34.

Analysts Set New Price Targets

MNKD has been the topic of several research reports. Wedbush reaffirmed an "outperform" rating and set a $10.00 price target on shares of MannKind in a research note on Wednesday, February 28th. HC Wainwright restated a "buy" rating and issued a $7.50 price target on shares of MannKind in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $6.50 price objective on shares of MannKind in a report on Friday, March 15th.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.